Given the transcriptional regulation ability and possible p53-modulating role of RFP, RFP might confer paclitaxel resistance to ovarian cancer cells through direct regulation of p53 function or transcriptional regulation of certain genes, such as miR-34c. The gene discussed is TP53; the disease is ovarian carcinoma.